Table 6.
MACE during 3-month follow up
| Items | Intracoronary prourokinase group (N = 25) | Control groups (N = 25) | P value |
|---|---|---|---|
| Total MACE, No. (%) | 3 (12.0) | 7 (28.0) | 0.157 |
| Cardiac death, No. (%) | 0 (0.0) | 0 (0.0) | – |
| Stent thrombosis, No. (%) | 0 (0.0) | 1 (4.0) | 1.000 |
| TVR, No. (%) | 0 (0.0) | 0 (0.0) | – |
| Heart failure, No. (%) | 2 (8.0) | 4 (16.0) | 0.667 |
| Malignant arrhythmia, No. (%) | 1 (4.0) | 2 (8.0) | 0.552 |
| Stroke, No. (%) | 0 (0.0) | 0 (0.0) | – |
Differences between two groups were determined by Fisher’s exact test. MACE major adverse cardiac events, TVR target vessel revascularization